As a biopharmaceutical company dedicated to innovative oncology therapies, Tosun Pharmaceutical is driven by frontier science and a strong innovation ethos to develop highly effective, precision medicines for cancer patients. The company builds on the latest advances in oncology research, systematically interrogating complex disease mechanisms to identify the most promising therapeutic targets and optimal combinations. Tosun Pharmaceutical focuses on advancing a third-generation antibody–drug conjugate (ADC) platform with the ambition of delivering globally competitive, best-in-class products. Beyond pursuing effective tumor control and clinical efficacy, the company commits to improve patients’ quality of life and long-term outcomes—bringing new hope to cancer patients worldwide and moving decisively toward its goal of becoming a leader in next-generation oncology innovation.

Commenting on the successful completion of the angel round, Professor Yongjun Liu, Founder of Tosun Pharmaceutical, said: “I would like to express my sincere gratitude to our investment partners for their strong support and trust. This financing not only provides substantial resources to accelerate the R&D of our third-generation ADC programs, but also reflects the market’s confidence in our strategy of pursuing original innovation and deepening our focus in oncology. Building on this milestone, we will accelerate pipeline development and drug discovery process and strive to establish a globally competitive system for innovative oncology therapies. We are committed to living up to our partners’ expectations and delivering more effective treatment options for cancer patients in China and around the world.”

As an early supporter of Tosun Pharmaceutical and the lead investor in this round, Lily Zhang, Founder and CEO of TTM Capital, said: “We have consistently believed in Tosun Pharmaceutical’s core strategy of ‘frontier science driven by clinical needs.’ Our decision to lead this round reflects our deep conviction in the differentiated value of the company’s third-generation ADC platform. Professor Yongjun Liu is a prestigious leader who combines world-class academic achievement with deep experience in pharmaceutical industry. We particularly value the team’s distinctive R&D strategy in oncology—especially its strengths in multi-target design and differentiated payload innovation. This ability to tightly integrate cutting-edge science with unmet clinical needs is a critical advantage for Tosun Pharmaceutical as it competes on a global stage. TTM Capital will fully support, accompany, and empower Tosun Pharmaceutical to become a breakthrough innovator and a categorical leader in global oncology therapeutics.”

Professor Yongjun Liu

Professor Yongjun Liu is internationally recognized as a world class immunology expert and is among the most senior Chinese scientists to have held leadership roles at major multinational biopharmaceutical companies. Over a distinguished academic and industry career, he has served in a number of prominent positions, including Chief Scientific Officer (CSO) at AstraZeneca/MedImmune, Head of Research, Global R&D at Sanofi, President of Innovent Biologics, Director of the Baylor Institute for Immunology Research, and Chair of Cancer Immunology at The University of Texas MD Anderson Cancer Center, among others.

Against a backdrop of profound shifts in the global biopharmaceutical innovation landscape, Chinese drug developers are accelerating a transition from “fast-follow” approaches to original, first-in-class innovation. With a world-class scientific team led by Professor Liu and a differentiated development strategy in third-generation ADCs, Tosun Pharmaceutical is well positioned to achieve meaningful technological breakthroughs in oncology—injecting new momentum into the high-quality development of China’s biopharmaceutical industry. The company’s ability to attract strong interest from leading investors, including TTM Capital, further underscores a consistent market reality: companies with globally competitive, original innovation remain at the center of long-term venture capital’s attention and conviction.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.